Image pharmaphorum Editor Views & Analysis Artificial Intelligence for better antibody drugs: ready for... The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. Views & Analysis Capturing progress in haemophilia care If we look back just 70 years, the prognosis for patients with haemophilia was remarkably different to what it is today. Sales & Marketing Sponsored Unlocking the full power of data for Pharma The value of data has never been greater in healthcare. Patients Endometriosis: hidden suffering and disease burden Improving patient outcomes starts by listening to and understanding their needs. Load more results
Views & Analysis Artificial Intelligence for better antibody drugs: ready for... The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.
Views & Analysis Capturing progress in haemophilia care If we look back just 70 years, the prognosis for patients with haemophilia was remarkably different to what it is today.
Sales & Marketing Sponsored Unlocking the full power of data for Pharma The value of data has never been greater in healthcare.
Patients Endometriosis: hidden suffering and disease burden Improving patient outcomes starts by listening to and understanding their needs.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
